FDA Global Reliance Disclosure Program

✓ Medically reviewed | Published: | Evidence level: 1A
The US FDA has launched a Global Reliance Disclosure Program for medicines, according to Voice of Healthcare. Regulatory reliance generally means using the work of other trusted regulators to support decisions, and the new program focuses on disclosure. Exact requirements should be confirmed in FDA documents.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Pharmacology

Quick Facts

Program Focus
Reliance disclosure for medicines
Regulator
US FDA
Core Concept
Leveraging other regulators' work
Patient Impact
Depends on implementation

What is regulatory reliance for medicines?

Quick answer: Regulatory reliance is when a regulator takes into account the assessments or inspections of another trusted authority when making its own decisions.

Medicines are developed and manufactured across many countries, and no regulator can independently inspect or evaluate everything. Reliance, a concept promoted by the World Health Organization, allows an authority to leverage information from others, such as inspection reports or product assessments, while still keeping responsibility for its own decisions. It can reduce duplication and help regulators focus resources where risk is highest.

International frameworks such as the International Council for Harmonisation (ICH) and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) already support shared standards and cooperation. A disclosure program in this area, as described in the Voice of Healthcare headline, appears aimed at making the use of such external information more transparent. The specific obligations for manufacturers or applicants should be checked against the FDA's own announcements.

Why does transparency in global drug oversight matter?

Quick answer: Most medicines depend on global supply chains, so clear information about where regulatory evidence comes from supports quality, safety and trust.

A large share of active pharmaceutical ingredients and finished medicines used in the United States are made abroad, according to FDA statements. Inspections, quality systems and supply chain visibility are therefore central to preventing contaminated, substandard or falsified products from reaching patients. Disclosure measures can help regulators see how a product's evidence package relies on foreign assessments and where gaps might exist.

Transparency can also help identify drug shortage risks and manufacturing weak points earlier. At the same time, reliance must not weaken scrutiny: regulators need to ensure that any external assessment meets standards equivalent to their own. Critics of reliance approaches usually raise this point, and the balance will depend on how the program is implemented.

What could this mean for patients and drugmakers?

Quick answer: Patients may see no immediate change, while drugmakers could face new reporting expectations; benefits depend on how the program is run.

For patients, any effects are likely to be indirect. If reliance reduces duplicated reviews, it could help useful medicines reach the market more efficiently, though speed should never come at the expense of safety. Stronger visibility into foreign manufacturing and review information could support quality oversight over time.

For companies, a disclosure program may add documentation tasks, particularly for those with products evaluated by multiple regulators. Industry groups and regulators will watch how the FDA defines scope, timelines and enforcement. Patients with questions about a specific medicine's quality should speak to a pharmacist or physician, and can find safety communications and recalls on the FDA website.

Frequently Asked Questions

There is no immediate change for patients. The program is about regulatory transparency, and any quality benefits will depend on how it is implemented.

It means a regulator considers the work of another trusted authority, such as an inspection or assessment, while keeping responsibility for its own decision.

The FDA's website and Federal Register notices provide official program details, including scope and requirements.

References

  1. Voice of Healthcare. US FDA Launches Global Reliance Disclosure Program for Medicines. November 2026.
  2. World Health Organization. Good Reliance Practices in the Regulation of Medical Products.
  3. U.S. Food and Drug Administration. Drug supply chain and inspection information.